Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics
<i>Fasciola hepatica</i>, the causative agent of fasciolosis, is a global threat to public health, animal welfare, agricultural productivity, and food security. In the ongoing absence of a commercial vaccine, independent emergences of anthelmintic-resistant parasite populations worldwide...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/25/15/3477 |
| _version_ | 1797560765059694592 |
|---|---|
| author | Clare F. Collett Russell M. Morphew David Timson Helen C. Phillips Peter M. Brophy |
| author_facet | Clare F. Collett Russell M. Morphew David Timson Helen C. Phillips Peter M. Brophy |
| author_sort | Clare F. Collett |
| collection | DOAJ |
| description | <i>Fasciola hepatica</i>, the causative agent of fasciolosis, is a global threat to public health, animal welfare, agricultural productivity, and food security. In the ongoing absence of a commercial vaccine, independent emergences of anthelmintic-resistant parasite populations worldwide are threatening the sustainability of the few flukicides presently available, and particularly triclabendazole (TCBZ) as the drug of choice. Consequently, prognoses for future fasciolosis control and sustained TCBZ application necessitate improvements in diagnostic tools to identify anthelmintic efficacy. Previously, we have shown that proteomic fingerprinting of <i>F. hepatica</i> excretory/secretory (ES) products offered new biomarkers associated with in vitro TCBZ-sulfoxide (SO) recovery or death. In the current paper, two of these biomarkers (calreticulin (CRT) and triose phosphate isomerase (TPI)) were recombinantly expressed and evaluated to measure TCBZ efficacy via a novel approach to decipher fluke molecular phenotypes independently of molecular parasite resistance mechanism(s), which are still not fully characterised or understood. Our findings confirmed the immunoreactivity and diagnostic potential of the present target antigens by sera from TCBZ-susceptible (TCBZ-S) and TCBZ-resistant (TCBZ-R) <i>F. hepatica</i> experimentally infected sheep. |
| first_indexed | 2024-03-10T18:05:07Z |
| format | Article |
| id | doaj.art-58523ece228b4e2cbca4141aa17d81d9 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T18:05:07Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-58523ece228b4e2cbca4141aa17d81d92023-11-20T08:33:06ZengMDPI AGMolecules1420-30492020-07-012515347710.3390/molecules25153477Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy DiagnosticsClare F. Collett0Russell M. Morphew1David Timson2Helen C. Phillips3Peter M. Brophy4Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth SY23 3DA, UKInstitute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth SY23 3DA, UKSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKInstitute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth SY23 3DA, UKInstitute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth SY23 3DA, UK<i>Fasciola hepatica</i>, the causative agent of fasciolosis, is a global threat to public health, animal welfare, agricultural productivity, and food security. In the ongoing absence of a commercial vaccine, independent emergences of anthelmintic-resistant parasite populations worldwide are threatening the sustainability of the few flukicides presently available, and particularly triclabendazole (TCBZ) as the drug of choice. Consequently, prognoses for future fasciolosis control and sustained TCBZ application necessitate improvements in diagnostic tools to identify anthelmintic efficacy. Previously, we have shown that proteomic fingerprinting of <i>F. hepatica</i> excretory/secretory (ES) products offered new biomarkers associated with in vitro TCBZ-sulfoxide (SO) recovery or death. In the current paper, two of these biomarkers (calreticulin (CRT) and triose phosphate isomerase (TPI)) were recombinantly expressed and evaluated to measure TCBZ efficacy via a novel approach to decipher fluke molecular phenotypes independently of molecular parasite resistance mechanism(s), which are still not fully characterised or understood. Our findings confirmed the immunoreactivity and diagnostic potential of the present target antigens by sera from TCBZ-susceptible (TCBZ-S) and TCBZ-resistant (TCBZ-R) <i>F. hepatica</i> experimentally infected sheep.https://www.mdpi.com/1420-3049/25/15/3477fasciolosistriclabendazolediagnosticsbiomarkercalreticulintriose phosphate isomerase |
| spellingShingle | Clare F. Collett Russell M. Morphew David Timson Helen C. Phillips Peter M. Brophy Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics Molecules fasciolosis triclabendazole diagnostics biomarker calreticulin triose phosphate isomerase |
| title | Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics |
| title_full | Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics |
| title_fullStr | Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics |
| title_full_unstemmed | Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics |
| title_short | Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics |
| title_sort | pilot evaluation of two i fasciola hepatica i biomarkers for supporting triclabendazole tcbz efficacy diagnostics |
| topic | fasciolosis triclabendazole diagnostics biomarker calreticulin triose phosphate isomerase |
| url | https://www.mdpi.com/1420-3049/25/15/3477 |
| work_keys_str_mv | AT clarefcollett pilotevaluationoftwoifasciolahepaticaibiomarkersforsupportingtriclabendazoletcbzefficacydiagnostics AT russellmmorphew pilotevaluationoftwoifasciolahepaticaibiomarkersforsupportingtriclabendazoletcbzefficacydiagnostics AT davidtimson pilotevaluationoftwoifasciolahepaticaibiomarkersforsupportingtriclabendazoletcbzefficacydiagnostics AT helencphillips pilotevaluationoftwoifasciolahepaticaibiomarkersforsupportingtriclabendazoletcbzefficacydiagnostics AT petermbrophy pilotevaluationoftwoifasciolahepaticaibiomarkersforsupportingtriclabendazoletcbzefficacydiagnostics |